1. Homepagina
  2. Aandelen
  3. Hongkong
  4. Hong Kong Stock Exchange
  5. Keymed Biosciences Inc.
  6. Nieuws
  7. Andere talen
    2162   KYG5252B1023

KEYMED BIOSCIENCES INC.

(2162)
  Rapport
Vertraagde tijd Hong Kong Stock Exchange  -  10:08 12-08-2022
32.15 HKD    0.00%
15/06Keymed Biosciences Inc. Ontvangt subsidies van Center for Drug Evaluation van de National Medical Products Administration voor CM310
CI
10/06Keymed Biosciences kondigt de toediening aan van de eerste patiënt in de Fase I studie met het bispecifieke antilichaam CM350
CI
20/04U.S. Food and Drug Administration verleent CMG901 Fast Track aanwijzing als monotherapie voor de behandeling van niet-resectabele of uitgezaaide maagkanker en kanker van de gastro-oesofageale junctie
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op KEYMED BIOSCIENCES INC.
07/07Certain Ordinary Shares of Keymed Biosciences Inc. are subject to a Lock-Up Agreement E..
06/07Keymed Bio to Subscribe to JP Morgan's Bond Offering
16/06Keymed Biosciences Obtains Therapy Designation for Antibody Injection
15/06Keymed Biosciences Inc. Receives Grants from Center for Drug Evaluation of the National..
10/06Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Ant..
20/04U.S. Food and Drug Administration Grants CMG901 Fast Track Designation as Monotherapy f..
19/04US FDA Grants Fast Track Designation to Keymed Bio's Gastric Cancer Drug Candidate
12/04KeyMed Biosciences Gets US FDA Orphan Drug Designation for Gastric Cancer Drug Candidat..
30/03Keymed's Chronic Sinusitis Treatment Shows Positive Outcomes in Clinical Trial
30/03Keymed Biosciences Inc. Announces Phase II Clinical Study of its Self-Developed Class1 ..
29/03Keymed Biosciences Inc. Announces Executive Changes
29/03Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2..
29/03Keymed Biosciences Inc. Announces Resignation of Dong Lyu as Non-Executive Director
07/03Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
21/02Hang Seng Index Adds Lenovo, Nongfu Spring as Constituents; SenseTime, XPeng Admitted t..
18/02Keymed Bio Joins Hang Seng Family of Indexes
07/01Certain Ordinary Shares of Keymed Biosciences Inc. are subject to a Lock-Up Agreement E..
03/01Certain Ordinary Shares of Keymed Biosciences Inc. are subject to a Lock-Up Agreement E..
2021KEYMED BIOSCIENCES INC.(SEHK : 2162) added to S&P Global BMI Index
2021Keymed Biosciences Chairman, Controlling Shareholder Ups Stake in Firm
2021Keymed's Atopic Dermatitis Treatment Shows Positive Results in Clinical Trial
2021Keymed Biosciences Inc. Announces Positive Results from Cm310 Atopic Dermatitisphase II..
2021CSPC Pharma Strikes Licensing Deal for China Rights to Keymed Bio's Allergy Drug
2021Keymed Biosciences' Asthma, Atopic Dermatitis Treatment Gets Positive Results in Phase ..
2021Keymed Biosciences Inc. Announces Positive Results from Phase I Clinical Study of CM326
2021KEYMED BIOSCIENCES : Partners With CSPC Pharmaceutical to Develop Potential Nervous System..
2021KEYMED BIOSCIENCES' : H1 Loss Expands
2021Keymed Biosciences Inc. Announces Unaudited Consolidated Earnings Result for the Six Mo..
2021KEYMED BIOSCIENCES : Bio Raises Nearly $58 Million from Full Exercise of Hong Kong IPO's O..
2021Keymed Biosciences Inc. has completed an IPO in the amount of HKD 3.105498 billion.
2021Keymed Biosciences Inc. has filed an IPO in the amount of HKD 3.105498 billion.